Related Experiment Video
Updated: Feb 14, 2026

Perspectives on Neuroscience
Published on: July 31, 2007
Bronchiectasis: new therapies and new perspectives
James D Chalmers1, Sanjay H Chotirmall2
1Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Abstract:
European Respiratory Society guidelines for the management of adult bronchiectasis highlight the paucity of treatment options available for patients with this disorder. No treatments have been licensed by regulatory agencies worldwide, and most therapies used in clinical practice are based on very little evidence. Development of new treatments is needed urgently. We did a systematic review of scientific literature and clinical trial registries to identify agents in early-to-late clinical development for bronchiectasis in adults. In this Review, we discuss the mechanisms and potential roles of emerging therapies, including drugs that target airway and systemic inflammation, mucociliary clearance, and epithelial dysfunction. To ensure these treatments achieve success in randomised clinical trials-and therefore reach patients-we propose a reassessment of the current approach to bronchiectasis. Although understanding of the pathophysiology of bronchiectasis is at an early stage, we argue that bronchiectasis is a heterogeneous disease with many different biological mechanisms that drive disease progression (endotypes), and therefore the so-called treatable traits approach used in asthma and chronic obstructive pulmonary disease could be applied to bronchiectasis, with future trials targeted at the specific disease subgroups most likely to benefit.
Insights
New treatments for adult bronchiectasis are urgently needed. This review identifies emerging therapies and proposes a "treatable traits" approach for clinical trials to better target patient subgroups.
Area of Science:
- Pulmonology
- Clinical Pharmacology
Background:
- Current management of adult bronchiectasis lacks licensed treatments and relies on therapies with limited evidence.
- There is an urgent need for novel therapeutic strategies to address the limited treatment options for bronchiectasis.
Purpose of the Study:
- To identify emerging therapeutic agents in clinical development for adult bronchiectasis.
- To discuss the mechanisms and potential roles of these novel therapies.
- To propose an optimized clinical trial strategy for bronchiectasis.
Main Methods:
- Systematic review of scientific literature.
- Screening of clinical trial registries for agents in development for adult bronchiectasis.
Main Results:
- Identified several emerging therapies targeting airway inflammation, systemic inflammation, mucociliary clearance, and epithelial dysfunction.
- Discussed the mechanisms of action and potential clinical applications of these novel agents.
- Highlighted the heterogeneity of bronchiectasis, suggesting distinct endotypes.
Conclusions:
- Adult bronchiectasis requires new treatments, with several promising agents in development.
- A 'treatable traits' approach, similar to asthma and COPD, could improve the success of future clinical trials by targeting specific patient subgroups.
- Reassessing the current approach to bronchiectasis clinical trials is crucial for advancing patient care.
Related Concept Videos
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Social Cognitive Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
The Behavioral Perspective on Personality
Gene Therapy
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...

